ORGS vs. LUMO, TCRT, MEIP, SYBX, BIVI, NRBO, BNTC, KALA, CPIX, and COCP
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Lumos Pharma (LUMO), Alaunos Therapeutics (TCRT), MEI Pharma (MEIP), Synlogic (SYBX), BioVie (BIVI), NeuroBo Pharmaceuticals (NRBO), Benitec Biopharma (BNTC), KALA BIO (KALA), Cumberland Pharmaceuticals (CPIX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
22.6% of Orgenesis shares are held by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 25.4% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Lumos Pharma has a consensus price target of $18.00, indicating a potential upside of 608.66%. Given Lumos Pharma's higher probable upside, analysts clearly believe Lumos Pharma is more favorable than Orgenesis.
In the previous week, Lumos Pharma had 6 more articles in the media than Orgenesis. MarketBeat recorded 6 mentions for Lumos Pharma and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 beat Lumos Pharma's score of -0.16 indicating that Orgenesis is being referred to more favorably in the media.
Lumos Pharma received 33 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
Orgenesis has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Lumos Pharma has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Orgenesis has a net margin of -1,010.50% compared to Lumos Pharma's net margin of -2,434.69%. Lumos Pharma's return on equity of -119.87% beat Orgenesis' return on equity.
Summary
Lumos Pharma beats Orgenesis on 11 of the 17 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
